Key Drivers
- High margins
- Strong cash flow
- Debt-free balance sheet
AIAI Summary
ISRG is now better viewed as a platform refresh story than a pure growth premium—revenue is outpacing procedures thanks to stronger monetization and the da Vinci 5 mix, but with the stock already re-rating down and valuation still demanding perfection, the key tradeoff is whether management can keep revenue growth ahead of procedure growth without any execution slip.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Strong cash flow
- •Debt-free balance sheet
ISRG delivered exceptional profitability, cash generation, and balance-sheet strength, but the stock looks expensive at a steep premium to its already strong fundamentals.
Price Behavior
Key Price Behavior Insights:
- •Downtrend intact
- •$420 support
- •Failed rebound
ISRG remains in a short-term downtrend, with ~$420 acting as support and $450-$453 as resistance, so only a sustained reclaim of $450 would improve the setup.
Roughly 10% decline over last month after repeated failed rebounds
Sentiment & News
Key News Insights:
- •Q1 Beat
- •Platform Refresh
- •Valuation Debate
ISRG posted a strong Q1 beat with 23% revenue growth and solid procedure momentum, but the stock remains caught between durable product-led upside and recurring valuation concerns.
Strong operating performance should support the shares, but further upside may be limited unless growth continues to outpace expectations
Similar Companies in Healthcare
Other companies in the same sector with AI ratings